Genmab — Maj 2017
-
det var nu mere en generel application af antistoffer, og ikke bare cd38
-
joeh - det lyder i hvert fald ikke usandsynligt, at det er HIV, når talen falder på Gilead
-
Deres cancer franchise er på selv de bedste dage voldsomt tynd
-
de har nu ikke mange mAb'er på vej... http://www.gilead.com/research/pipeline
-
med den brede portefølje GILD har i deres pipeline, kan vi vel næsten kun gå ud fra at de er ivrige efter at fylde noget kød på den
-
-
Ofatumumab not completely forgotten, in new combo trial NCT03136146 acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LL). https://clinicaltrials.gov/ct2/show/NCT03136146?term=Ofatumumab&recr=Open&rcv_s=04%2F20
%2F2017&rank=1 -
lets try that link again... https://clinicaltrials.gov/ct2/show/NCT03136146?t
erm=Ofatumumab&recr=Open&rcv_s=04%2F20%2F2017&rank=1 -
præcis samme historie som i går
-
-
Lyder flot Darvin. Men Teprotumumab kan vist ikke nå ret mange patienter. Og derfor ingen interesse fra Big Pharma!
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind